Table 10: Body of evidence assessment matrix A B C D Excellent Good Satisfactory Poor Evidence base several level I or II one or two level II level III studies with level IV studies, or studies with low studies with low risk of low risk of bias, or level I to III studies risk of bias bias or a SR/multiple level I or II studies with high risk of bias level III studies with with moderate risk of low risk of bias bias Consistency all studies most studies some inconsistency evidence is consistent consistent and reflecting genuine inconsistent inconsistency may be uncertainty around explained clinical question Clinical impact very large substantial moderate slight or restricted Generalizability population/s population/s studied in population/s studied in population/s studied in studied in body of the body of evidence body of evidence body of evidence evidence are the are similar to the different to target different to target same as the target population population for population and hard to target population guideline but it is judge whether it is clinically sensible to sensible to generalise apply this evidence to to target population target population Applicability directly applicable applicable to probably applicable to not applicable to to Australian Australian healthcare Australian healthcare Australian healthcare healthcare context with few context with some context context caveats caveats Adapted from () Expert advice An advisory panel was established to provide guidance to the evaluators to ensure that the assessment is clinically relevant and takes into account consumer interests. Membership of the advisory panel is provided at Appendix D.
Table 10: Body of evidence assessment matrix A B C D Excellent Good Satisfactory Poor Evidence base several level I or II studies with low risk of bias one or two level II studies with low risk of bias or a SR/multiple level III studies with low risk of bias level III studies with low risk of bias, or level I or II studies with moderate risk of bias level IV studies, or level I to III studies with high risk of bias Consistency all studies consistent most studies consistent and inconsistency may be explained some inconsistency reflecting genuine uncertainty around clinical question evidence is inconsistent Clinical impact very large substantial moderate slight or restricted Generalizability population/s studied in body of evidence are the same as the target population population/s studied in the body of evidence are similar to the target population population/s studied in body of evidence different to target population for guideline but it is clinically sensible to apply this evidence to target population population/s studied in body of evidence different to target population and hard to judge whether it is sensible to generalise to target population Applicability directly applicable to Australian healthcare context applicable to Australian healthcare context with few caveats probably applicable to Australian healthcare context with some caveats not applicable to Australian healthcare context Adapted from () Expert advice An advisory panel was established to provide guidance to the evaluators to ensure that the assessment is clinically relevant and takes into account consumer interests. Membership of the advisory panel is provided at Appendix D.
1313_BMDusingDXAAromataseInhibitor_AttA_FinalAssessmentReport%20-accessible.docx